BIOHEART-B (02185) Schedules 26 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express

Mar 16

Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes:

• Approval of the consolidated annual results for the financial year ended 31 December 2025. • Review and potential recommendation of a final dividend for shareholders.

The meeting will be chaired by Mr. Philip Li Wang, who serves as both Chairman and executive director. The current Board comprises three executive directors—Mr. Philip Li Wang, Mr. Yunqing Wang and Ms. Peili Wang—alongside three independent non-executive directors: Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang.

Further details, including the audited financial statements and any final dividend proposal, are expected to be released following Board approval.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1132847716"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132847716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132847716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132847716","market":"us","top_or_hot":-1,"title":"BIOHEART-B (02185) Schedules 26 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes:</p>\n<p>• Approval of the consolidated annual results for the financial year ended 31 December 2025.  \n• Review and potential recommendation of a final dividend for shareholders.</p>\n<p>The meeting will be chaired by Mr. Philip Li Wang, who serves as both Chairman and executive director. The current Board comprises three executive directors—Mr. Philip Li Wang, Mr. Yunqing Wang and Ms. Peili Wang—alongside three independent non-executive directors: Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang.</p>\n<p>Further details, including the audited financial statements and any final dividend proposal, are expected to be released following Board approval.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOHEART-B (02185) Schedules 26 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOHEART-B (02185) Schedules 26 March 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-16 16:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes:</p>\n<p>• Approval of the consolidated annual results for the financial year ended 31 December 2025.  \n• Review and potential recommendation of a final dividend for shareholders.</p>\n<p>The meeting will be chaired by Mr. Philip Li Wang, who serves as both Chairman and executive director. The current Board comprises three executive directors—Mr. Philip Li Wang, Mr. Yunqing Wang and Ms. Peili Wang—alongside three independent non-executive directors: Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang.</p>\n<p>Further details, including the audited financial statements and any final dividend proposal, are expected to be released following Board approval.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02185","symbol_name":"百心安-B","start_time":0,"source_url":"","article_id":"1132847716","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132847716","pubTimestamp":1773650473,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes: • Approval of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02185":"百心安-B"},"translate_title":"BIOHEART-B(02185)定于2026年3月26日召开董事会批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"Shanghai Bio-heart Biological Technology Co., Ltd. (BIOHEART-B, 02185) has announced that its board of directors will convene on 26 March 2026 in Shanghai, PRC. The agenda includes:\n• Approval of the consolidated annual results for the financial year ended 31 December 2025.  \n• Review and potential recommendation of a final dividend for shareholders.\nThe meeting will be chaired by Mr. Philip Li Wang, who serves as both Chairman and executive director. The current Board comprises three executive directors—Mr. Philip Li Wang, Mr. Yunqing Wang and Ms. Peili Wang—alongside three independent non-executive directors: Mr. Yiqing Chen, Mr. Xubo Lu and Mr. Yifei Jiang.\nFurther details, including the audited financial statements and any final dividend proposal, are expected to be released following Board approval.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}